{"gene":"DR1","run_date":"2026-06-09T23:54:42","timeline":{"discoveries":[{"year":1992,"finding":"DR1 (Down-regulator of transcription 1) interacts directly with the TATA-binding protein (TBP), and this association represses both basal and activated transcription by blocking the association of TFIIA and/or TFIIB with TBP, preventing formation of a transcription-competent preinitiation complex. DR1 activity is associated with a 19 kDa phosphoprotein, and phosphorylation of DR1 affects its interaction with TBP.","method":"Biochemical purification, in vitro transcription repression assay, Co-immunoprecipitation, cDNA cloning, phosphorylation analysis","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1/2 / Strong — original discovery paper with multiple orthogonal methods (in vitro transcription assay, protein-protein interaction, cDNA cloning), foundational mechanistic result replicated by multiple subsequent studies","pmids":["1339312"],"is_preprint":false},{"year":1994,"finding":"DR1 directly interacts with the multiprotein TFIID complex (not just free TBP) in vivo via a yeast two-hybrid assay. Two distinct domains of DR1 are required for repression: a TBP-binding domain and an alanine-rich domain. DR1-mediated repression can be reversed by overexpression of TBP in vivo, and Dr1 can repress transcription from both TATA-containing and TATA-less promoters.","method":"Yeast two-hybrid, in vitro binding assays, transient transfection, domain-deletion mutagenesis","journal":"Genes & Development","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods (yeast two-hybrid, in vivo overexpression rescue, mutagenesis) in a single focused study, confirmed by subsequent papers","pmids":["7958881"],"is_preprint":false},{"year":1995,"finding":"NC2 (negative cofactor 2) is identical to DR1. TBP residues Lys-133, Lys-145, and Lys-151 in the basic repeat region are important for NC2/DR1 interaction, whereas Leu-189 is required for TFIIB interaction, demonstrating that distinct TBP surface regions mediate interactions with DR1/NC2 versus TFIIB.","method":"TBP mutagenesis, in vitro binding assays, transcription reconstitution","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis combined with in vitro reconstitution, establishes molecular identity of NC2=DR1 and maps binding surfaces on TBP","pmids":["7738039"],"is_preprint":false},{"year":1996,"finding":"A DR1-associated polypeptide (DRAP1, also called NC2-alpha or NC2β partner) was isolated and functions as a corepressor requiring interaction with DR1. Heterodimer formation between DRAP1 and DR1 depends on a histone fold motif at the amino terminus of both polypeptides. The DRAP1–DR1 complex increases the stability of the DR1–TBP–TATA motif complex and more effectively precludes TFIIA and/or TFIIB entry into preinitiation complexes.","method":"Protein purification, Co-immunoprecipitation, in vitro transcription assay, domain analysis","journal":"Genes & Development","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — biochemical purification, functional reconstitution, and domain mapping; replicated by subsequent studies confirming the DR1/DRAP1 heterodimer","pmids":["8608938"],"is_preprint":false},{"year":1994,"finding":"DR1 selectively represses RNA polymerase II and RNA polymerase III transcription by binding TBP and blocking polymerase-specific factor interactions, but does not inhibit RNA polymerase I transcription under the same conditions, enabling coordinate regulation of Pol II and Pol III while sparing Pol I.","method":"In vitro transcription assays with purified components, selective depletion/add-back experiments","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstituted transcription system with three polymerases compared, single lab but rigorous biochemical approach","pmids":["7939686"],"is_preprint":false},{"year":1994,"finding":"Adenovirus E1A 12S protein disrupts the DR1–TBP interaction in a manner dependent on N-terminal E1A sequences, thereby allowing productive TBP–TFIIA interaction and relieving DR1-mediated repression of the hsp70 promoter in vivo.","method":"Co-immunoprecipitation, in vitro protein interaction assay, transient transfection with wild-type and mutant E1A","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — Co-IP and in vivo functional rescue, two methods, single lab","pmids":["8022773"],"is_preprint":false},{"year":1996,"finding":"Human cytomegalovirus IE2 protein overcomes DR1-mediated transcriptional repression of the hsp70 promoter in vivo. IE2 physically interacts with DR1 both in vivo and in vitro, and can prevent DR1-mediated inhibition of TBP DNA binding in vitro, suggesting a mechanism for TATA-dependent IE2 transactivation.","method":"Co-immunoprecipitation (in vivo and in vitro), in vitro TBP DNA binding assay, transient transfection","journal":"Journal of Virology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — multiple methods (Co-IP in vivo and in vitro, functional in vitro binding assay), single lab","pmids":["8648740"],"is_preprint":false},{"year":1997,"finding":"DR1 contains two functional domains: a tethering domain that interacts with TBP (required to direct the repressor to the promoter) and a repression domain (glutamine-alanine rich). The repression domain alone (65 aa), fused to the Gal4 DNA-binding domain, represses transcription from TATA-containing and TATA-less promoters. DRAP1 enhances DR1-mediated repression only when the tethering domain is present.","method":"Domain deletion and fusion constructs, in vitro transcription assays, transient transfection","journal":"Molecular and Cellular Biology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — domain-swapping mutagenesis combined with functional assays in vitro and in vivo; replicated and extended prior work","pmids":["8972183"],"is_preprint":false},{"year":1997,"finding":"The yeast DR1/DRAP1 homologs (YDR1/BUR6) are encoded by two essential genes. Human DR1 and DRAP1 can rescue lethality caused by deletion of the yeast genes, but human DRAP1 only functions when human DR1 is co-expressed. Overexpression of YDR1 decreases mRNA accumulation and impairs growth, rescuable by TBP overexpression. DR1 overexpression affects Pol II and Pol III but not Pol I transcript levels in vivo, demonstrating it is a global repressor in vivo.","method":"Yeast genetics (deletion, rescue by human homologs), in vitro reconstituted transcription, in vivo mRNA quantification","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in yeast combined with in vitro transcription reconstitution; replicates earlier in vitro findings in a cellular system","pmids":["9023340"],"is_preprint":false},{"year":1996,"finding":"The transcriptional repressor E4BP4 interacts specifically with DR1 through its C-terminal repression domain. E4BP4 mutants deficient in transcriptional repression are also deficient in DR1 binding, suggesting DR1 mediates at least part of E4BP4's repression activity.","method":"Co-immunoprecipitation/pull-down, transient transfection with repression domain mutants","journal":"Nucleic Acids Research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — single Co-IP/pulldown, supported by correlation between DR1-binding and repression function via mutagenesis","pmids":["8836190"],"is_preprint":false},{"year":2000,"finding":"DR1 (NC2β) forms a complex with CTD-hyperphosphorylated RNA polymerase IIO (but not unphosphorylated RNAP IIA or CTD-less RNAP IIB). In unfractionated HeLa nuclear extracts, immunodepletion of NC2/DR1 does not significantly affect basal transcription but dramatically reduces activated transcription, revealing an unexpected positive role for DR1 in activated transcription in the context of native nuclear extracts.","method":"Co-immunoprecipitation with purified factors, immunodepletion from HeLa nuclear extracts, in vitro transcription assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — reconstituted and native extract biochemistry, co-IP with purified factors; single lab, novel finding regarding DR1 positive role","pmids":["10852970"],"is_preprint":false},{"year":2002,"finding":"Hypoxic stress induces upregulation of NC2 (Dr1/DrAP1) protein, which binds core promoters and blocks preinitiation complex assembly and RNA Pol II CTD phosphorylation. Immunodepletion of NC2β/Dr1 from hypoxic cell extracts rescues repressed transcription without affecting normoxic transcription, demonstrating that hypoxia actively represses transcription via Dr1.","method":"In vitro transcription reconstitution, immunodepletion, immunoblot, hypoxic cell extract analysis","journal":"Journal of Biological Chemistry","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — functional immunodepletion rescue experiment combined with in vitro transcription; single lab","pmids":["12477712"],"is_preprint":false},{"year":1999,"finding":"A negative cofactor containing Dr1/p19 (heterotetramer with a 30-kDa partner, proposed as DRAP1 homolog) forms a complex with TBP on DNA protecting ~150 bp around the promoter from DNase I cleavage. TFIIA reverses this repression and alters complex conformation in a promoter-specific fashion: on the adenovirus MLP but not on the immunoglobulin mu promoter.","method":"Protein purification, DNase I footprinting, in vitro transcription assay, TFIIA competition","journal":"Journal of Biological Chemistry","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — biochemical reconstitution with footprinting and transcription assays; single lab, promoter-specific distinction established","pmids":["8702484"],"is_preprint":false},{"year":2015,"finding":"DR1 (the transcriptional repressor) is a positive host factor for influenza A virus (IAV) replication. Knockdown of DR1 reduces viral RNA and protein production. DR1 suppresses IFN-β induction (and downstream ISG expression) in normal cells, and also directly enhances viral RNA-dependent RNA polymerase (RdRp) activity by physically associating with all three subunits of the viral RdRp complex.","method":"Genome-wide RNAi screen, siRNA knockdown, genome-wide transcriptomics, viral RNA replication biochemical assay, Co-immunoprecipitation of DR1 with viral RdRp subunits","journal":"Journal of Virology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — RNAi screen validated by targeted KD, transcriptomics, biochemical RdRp assay, and Co-IP; single lab","pmids":["25589657"],"is_preprint":false},{"year":2018,"finding":"DR1 is a direct target of miR-203, which is upregulated during influenza A virus (H5N1) infection. Silencing DR1 by siRNA in miR-203 knockout cells inhibits H5N1 replication similarly to miR-203 overexpression, confirming DR1's role as a positive regulator of IAV replication downstream of miR-203.","method":"miRNA overexpression/knockout, siRNA knockdown, viral replication assay, target validation","journal":"Scientific Reports","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — functional genetic validation of DR1 as miR-203 target with siRNA rescue experiment; single lab","pmids":["29717211"],"is_preprint":false}],"current_model":"DR1 (Down-regulator of transcription 1, also NC2-beta/NC2B) is a transcriptional repressor that binds TBP via a histone-fold-containing tethering domain, blocking recruitment of TFIIA and TFIIB to preinitiation complexes, thereby repressing RNA Pol II and Pol III but not Pol I transcription; its repressor activity is enhanced by heterodimerization with DRAP1 (NC2-alpha) through their shared histone fold motifs, can be relieved by viral proteins (adenovirus E1A, HCMV IE2) that disrupt the DR1–TBP interaction, and is physiologically induced by hypoxia; DR1 also physically associates with all three subunits of the influenza A virus RdRp complex, directly facilitating viral RNA replication while simultaneously suppressing host IFN-β induction."},"narrative":{"mechanistic_narrative":"DR1 (Down-regulator of transcription 1, identical to NC2-beta/NC2) is a global transcriptional repressor that acts at the core of the RNA polymerase II preinitiation complex by binding directly to the TATA-binding protein (TBP) and to the TFIID complex [PMID:1339312, PMID:7958881, PMID:7738039]. It engages a distinct surface of TBP (basic-repeat residues Lys-133/145/151) separate from the TFIIB-interaction surface, and by occupying TBP it blocks the entry of TFIIA and TFIIB, preventing assembly of a transcription-competent complex on both TATA-containing and TATA-less promoters [PMID:1339312, PMID:7958881, PMID:7738039]. The protein is functionally bipartite: a TBP-binding tethering domain directs it to the promoter while a glutamine/alanine-rich repression domain delivers the silencing activity, the latter sufficient to repress transcription when independently tethered [PMID:8972183]. Repression is potentiated by heterodimerization with DRAP1 (NC2-alpha) through a shared N-terminal histone-fold motif, which stabilizes the DR1-TBP-TATA complex and more effectively excludes the general factors; this exclusion is reversed by TFIIA in a promoter-specific manner [PMID:8608938, PMID:8972183, PMID:8702484]. DR1 selectively represses RNA polymerase II and III transcription while sparing Pol I, and this global repressive role is conserved, as the human protein and its yeast YDR1/BUR6 homologs are functionally interchangeable and essential [PMID:7939686, PMID:9023340]. DR1-mediated repression is a regulatory node exploited and modulated in physiological and pathogenic contexts: it is induced by hypoxic stress to actively shut down transcription [PMID:12477712], is relieved by viral activators adenovirus E1A and HCMV IE2 that disrupt the DR1-TBP interaction [PMID:8022773, PMID:8648740], and is co-opted as a positive host factor for influenza A virus, where DR1 associates with all three subunits of the viral RdRp to enhance viral RNA synthesis while suppressing IFN-beta induction [PMID:25589657, PMID:29717211].","teleology":[{"year":1992,"claim":"Established the founding mechanism: how a cellular factor could repress basal and activated transcription at the level of the general machinery rather than at specific activators.","evidence":"Biochemical purification, in vitro transcription repression, Co-IP and cDNA cloning identifying direct DR1-TBP binding that blocks TFIIA/TFIIB","pmids":["1339312"],"confidence":"High","gaps":["Domain organization of DR1 not yet mapped","Role of the 19 kDa phosphoprotein and phosphorylation regulation left unresolved"]},{"year":1994,"claim":"Resolved which polymerases DR1 acts on, showing selective repression of Pol II and Pol III but not Pol I, defining the scope of its global regulatory function.","evidence":"In vitro transcription with purified components comparing all three polymerases; in vivo TFIID interaction and TBP-overexpression rescue","pmids":["7939686","7958881"],"confidence":"High","gaps":["Basis for sparing Pol I not mechanistically explained","In vivo promoter occupancy not addressed"]},{"year":1995,"claim":"Unified NC2 and DR1 as one factor and mapped the TBP surfaces that distinguish DR1 binding from TFIIB binding, explaining the competitive mechanism.","evidence":"TBP mutagenesis with in vitro binding and transcription reconstitution","pmids":["7738039"],"confidence":"High","gaps":["Structural detail of the DR1-TBP-DNA complex not resolved at this stage"]},{"year":1996,"claim":"Identified DRAP1 as the obligate corepressor partner and established the histone-fold heterodimer as the active repressive unit that stabilizes the TBP-DNA complex.","evidence":"Protein purification, Co-IP, in vitro transcription and domain analysis; DNase I footprinting of the heterotetramer protecting ~150 bp","pmids":["8608938","8702484"],"confidence":"High","gaps":["Promoter-specific TFIIA reversal mechanism only partially defined","Stoichiometry and architecture on chromatin not established"]},{"year":1996,"claim":"Linked DR1 to a sequence-specific repressor (E4BP4), indicating DR1 can serve as the effector arm for promoter-targeted repressors.","evidence":"Co-IP/pull-down with E4BP4 repression-domain mutants showing correlated binding and repression","pmids":["8836190"],"confidence":"Medium","gaps":["Single Co-IP/pulldown without reciprocal in vitro reconstitution","Whether E4BP4 recruits DR1 to specific genes in vivo unknown"]},{"year":1997,"claim":"Dissected DR1 into a tethering domain and a separable repression domain, defining how promoter targeting and silencing activity are functionally partitioned.","evidence":"Domain-deletion and Gal4-fusion constructs with in vitro and in vivo transcription assays","pmids":["8972183"],"confidence":"High","gaps":["Molecular targets of the repression domain beyond blocking TFIIA/TFIIB not identified"]},{"year":1997,"claim":"Demonstrated in vivo and across evolution that DR1 is an essential global repressor, with conserved function between human and yeast homologs.","evidence":"Yeast genetics with human-homolog rescue, in vitro reconstituted transcription, in vivo mRNA quantification","pmids":["9023340"],"confidence":"High","gaps":["Gene-specific in vivo targets in higher eukaryotes not mapped"]},{"year":2000,"claim":"Revealed a context-dependent positive role: in native nuclear extracts DR1 associates with hyperphosphorylated Pol IIO and is required for activated transcription, complicating the purely repressive model.","evidence":"Co-IP with purified Pol II forms and immunodepletion from HeLa nuclear extracts with transcription readout","pmids":["10852970"],"confidence":"Medium","gaps":["Mechanism reconciling repressive and activating roles unresolved","Single-lab observation in native extracts"]},{"year":2002,"claim":"Placed DR1 in a physiological stress pathway, showing hypoxia induces NC2/Dr1 to actively shut down transcription via PIC blockade and reduced CTD phosphorylation.","evidence":"In vitro transcription reconstitution, immunodepletion rescue from hypoxic extracts, immunoblot","pmids":["12477712"],"confidence":"Medium","gaps":["Upstream signal inducing NC2/Dr1 not defined","Gene-selectivity of hypoxic repression not characterized"]},{"year":2015,"claim":"Uncovered a pro-viral function: DR1 is a host factor that both suppresses IFN-beta induction and directly enhances influenza A RdRp activity through physical association with the polymerase.","evidence":"Genome-wide RNAi screen, siRNA knockdown, transcriptomics, RdRp biochemical assay, Co-IP with all three RdRp subunits","pmids":["25589657"],"confidence":"Medium","gaps":["Whether RdRp enhancement is mechanistically separate from transcriptional repression unclear","Structural basis of DR1-RdRp interaction unknown","Single lab"]},{"year":2018,"claim":"Positioned DR1 within a host miRNA regulatory circuit, identifying it as a miR-203 target whose silencing limits H5N1 replication.","evidence":"miR-203 overexpression/knockout, siRNA knockdown with rescue, viral replication and target validation assays","pmids":["29717211"],"confidence":"Medium","gaps":["Direct miR-203:DR1 binding site validation limited","How DR1 levels are tuned during infection in vivo not established"]},{"year":null,"claim":"How DR1's repressive activity, its positive role in activated transcription, and its pro-viral RdRp-enhancing function are mechanistically integrated remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of DR1-DRAP1-TBP-DNA on native promoters","Genome-wide in vivo occupancy and gene-selectivity unmapped","Reconciliation of repressor versus activator/coactivator roles unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1,4,7,8]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,3,7]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[3,7]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[11,12]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,8]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,1,4,8]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[11]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[13,14]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[13]}],"complexes":["NC2 (DR1-DRAP1) repressor heterodimer"],"partners":["TBP","DRAP1","TFIID","E4BP4","RNA POLYMERASE II"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q01658","full_name":"Protein Dr1","aliases":["Down-regulator of transcription 1","Negative cofactor 2-beta","NC2-beta","TATA-binding protein-associated phosphoprotein"],"length_aa":176,"mass_kda":19.4,"function":"The association of the DR1/DRAP1 heterodimer with TBP results in a functional repression of both activated and basal transcription of class II genes. This interaction precludes the formation of a transcription-competent complex by inhibiting the association of TFIIA and/or TFIIB with TBP. Can bind to DNA on its own. Component of the ATAC complex, a complex with histone acetyltransferase activity on histones H3 and H4","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q01658/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/DR1","classification":"Common Essential","n_dependent_lines":1069,"n_total_lines":1208,"dependency_fraction":0.8849337748344371},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"ACTB","stoichiometry":0.2},{"gene":"MTMR2","stoichiometry":0.2},{"gene":"PARP1","stoichiometry":0.2},{"gene":"TBP","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/DR1","total_profiled":1310},"omim":[{"mim_id":"613815","title":"CYTOCHROME P450, FAMILY 21, SUBFAMILY A, POLYPEPTIDE 2; CYP21A2","url":"https://www.omim.org/entry/613815"},{"mim_id":"613373","title":"YEATS DOMAIN-CONTAINING PROTEIN 2; YEATS2","url":"https://www.omim.org/entry/613373"},{"mim_id":"611264","title":"CENTROMERIC PROTEIN W; CENPW","url":"https://www.omim.org/entry/611264"},{"mim_id":"602289","title":"DR1-ASSOCIATED PROTEIN 1; DRAP1","url":"https://www.omim.org/entry/602289"},{"mim_id":"601482","title":"DOWNREGULATOR OF TRANSCRIPTION 1, TBP-BINDING; DR1","url":"https://www.omim.org/entry/601482"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/DR1"},"hgnc":{"alias_symbol":["NC2-BETA","NC2B","NCB2"],"prev_symbol":[]},"alphafold":{"accession":"Q01658","domains":[{"cath_id":"1.10.20.10","chopping":"8-84","consensus_level":"medium","plddt":95.3956,"start":8,"end":84},{"cath_id":"1.20.5","chopping":"113-161","consensus_level":"medium","plddt":91.088,"start":113,"end":161}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q01658","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q01658-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q01658-F1-predicted_aligned_error_v6.png","plddt_mean":87.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=DR1","jax_strain_url":"https://www.jax.org/strain/search?query=DR1"},"sequence":{"accession":"Q01658","fasta_url":"https://rest.uniprot.org/uniprotkb/Q01658.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q01658/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q01658"}},"corpus_meta":[{"pmid":"8316295","id":"PMC_8316295","title":"Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1.","date":"1993","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8316295","citation_count":2028,"is_preprint":false},{"pmid":"8145819","id":"PMC_8145819","title":"Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide.","date":"1994","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8145819","citation_count":1394,"is_preprint":false},{"pmid":"1327537","id":"PMC_1327537","title":"All-trans and 9-cis retinoic acid induction of CRABPII transcription is mediated by RAR-RXR heterodimers bound to DR1 and DR2 repeated motifs.","date":"1992","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/1327537","citation_count":420,"is_preprint":false},{"pmid":"1339312","id":"PMC_1339312","title":"Dr1, a TATA-binding protein-associated phosphoprotein and inhibitor of class II gene transcription.","date":"1992","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/1339312","citation_count":350,"is_preprint":false},{"pmid":"1371238","id":"PMC_1371238","title":"The human class II MHC protein HLA-DR1 assembles as empty alpha beta heterodimers in the absence of antigenic peptide.","date":"1992","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/1371238","citation_count":299,"is_preprint":false},{"pmid":"2189723","id":"PMC_2189723","title":"Peptide binding to HLA-DR1: a peptide with most residues substituted to alanine retains MHC binding.","date":"1990","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/2189723","citation_count":299,"is_preprint":false},{"pmid":"7997880","id":"PMC_7997880","title":"Toxic shock syndrome toxin-1 complexed with a class II major histocompatibility molecule HLA-DR1.","date":"1994","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/7997880","citation_count":251,"is_preprint":false},{"pmid":"12096030","id":"PMC_12096030","title":"Exosomes bearing HLA-DR1 molecules need dendritic cells to efficiently stimulate specific T cells.","date":"2002","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12096030","citation_count":222,"is_preprint":false},{"pmid":"1402647","id":"PMC_1402647","title":"Identification of a motif for HLA-DR1 binding peptides using M13 display libraries.","date":"1992","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/1402647","citation_count":218,"is_preprint":false},{"pmid":"2963699","id":"PMC_2963699","title":"Structural model of HLA-DR1 restricted T cell antigen recognition.","date":"1988","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/2963699","citation_count":214,"is_preprint":false},{"pmid":"11060013","id":"PMC_11060013","title":"Structure of a covalently stabilized complex of a human alphabeta T-cell receptor, influenza HA peptide and MHC class II molecule, HLA-DR1.","date":"2000","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/11060013","citation_count":210,"is_preprint":false},{"pmid":"3260007","id":"PMC_3260007","title":"Molecular genetic analysis of nonclassic steroid 21-hydroxylase deficiency associated with HLA-B14,DR1.","date":"1988","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/3260007","citation_count":185,"is_preprint":false},{"pmid":"9091584","id":"PMC_9091584","title":"An HLA-DR1 transgene confers susceptibility to collagen-induced arthritis elicited with human type II collagen.","date":"1997","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9091584","citation_count":179,"is_preprint":false},{"pmid":"10698945","id":"PMC_10698945","title":"Structure of the RXR-RAR DNA-binding complex on the retinoic acid response element DR1.","date":"2000","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/10698945","citation_count":164,"is_preprint":false},{"pmid":"16492670","id":"PMC_16492670","title":"Functional inhibitory cross-talk between constitutive androstane receptor and hepatic nuclear factor-4 in hepatic lipid/glucose metabolism is mediated by competition for binding to the DR1 motif and to the common coactivators, GRIP-1 and PGC-1alpha.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16492670","citation_count":161,"is_preprint":false},{"pmid":"9351812","id":"PMC_9351812","title":"The class II MHC protein HLA-DR1 in complex with an endogenous peptide: implications for the structural basis of the specificity of peptide binding.","date":"1997","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/9351812","citation_count":140,"is_preprint":false},{"pmid":"23260142","id":"PMC_23260142","title":"Crystal structure of the HLA-DM-HLA-DR1 complex defines mechanisms for rapid peptide selection.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/23260142","citation_count":139,"is_preprint":false},{"pmid":"11864610","id":"PMC_11864610","title":"Structure of the Epstein-Barr virus gp42 protein bound to the MHC class II receptor HLA-DR1.","date":"2002","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/11864610","citation_count":134,"is_preprint":false},{"pmid":"1370684","id":"PMC_1370684","title":"Identification of HLA-DR1 beta chain residues critical for binding staphylococcal enterotoxins A and E.","date":"1992","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/1370684","citation_count":125,"is_preprint":false},{"pmid":"15468058","id":"PMC_15468058","title":"A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice.","date":"2004","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15468058","citation_count":125,"is_preprint":false},{"pmid":"9032323","id":"PMC_9032323","title":"The presence of host-derived HLA-DR1 on human immunodeficiency virus type 1 increases viral infectivity.","date":"1997","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/9032323","citation_count":124,"is_preprint":false},{"pmid":"3858829","id":"PMC_3858829","title":"DNA sequence and characterization of human class II major histocompatibility complex beta chains from the DR1 haplotype.","date":"1985","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/3858829","citation_count":117,"is_preprint":false},{"pmid":"8608938","id":"PMC_8608938","title":"Requirement of a corepressor for Dr1-mediated repression of transcription.","date":"1996","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/8608938","citation_count":115,"is_preprint":false},{"pmid":"23468504","id":"PMC_23468504","title":"Adeno-associated virus-mediated gene transfer leads to persistent hepatitis B virus replication in mice expressing HLA-A2 and HLA-DR1 molecules.","date":"2013","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/23468504","citation_count":105,"is_preprint":false},{"pmid":"2657745","id":"PMC_2657745","title":"Allorecognition of DR1 by T cells from a DR4/DRw13 responder mimics self-restricted recognition of endogenous peptides.","date":"1989","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2657745","citation_count":97,"is_preprint":false},{"pmid":"9207464","id":"PMC_9207464","title":"HLA-DR1-restricted bcr-abl (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates.","date":"1997","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9207464","citation_count":95,"is_preprint":false},{"pmid":"7958881","id":"PMC_7958881","title":"Structure-function analysis of the TBP-binding protein Dr1 reveals a mechanism for repression of class II gene transcription.","date":"1994","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/7958881","citation_count":93,"is_preprint":false},{"pmid":"1375272","id":"PMC_1375272","title":"Self-peptide released from class II HLA-DR1 exhibits a hydrophobic two-residue contact motif.","date":"1992","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/1375272","citation_count":93,"is_preprint":false},{"pmid":"11751969","id":"PMC_11751969","title":"HLA-DR1 (DRB1*0101) and DR4 (DRB1*0401) use the same anchor residues for binding an immunodominant peptide derived from human type II collagen.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11751969","citation_count":87,"is_preprint":false},{"pmid":"9023340","id":"PMC_9023340","title":"The Dr1/DRAP1 heterodimer is a global repressor of transcription in vivo.","date":"1997","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9023340","citation_count":86,"is_preprint":false},{"pmid":"7997881","id":"PMC_7997881","title":"Subsets of HLA-DR1 molecules defined by SEB and TSST-1 binding.","date":"1994","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/7997881","citation_count":85,"is_preprint":false},{"pmid":"2492329","id":"PMC_2492329","title":"Co-recognition of endogenous antigens with HLA-DR1 by alloreactive human T cell clones.","date":"1989","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/2492329","citation_count":83,"is_preprint":false},{"pmid":"10636922","id":"PMC_10636922","title":"Determinants of the peptide-induced conformational change in the human class II major histocompatibility complex protein HLA-DR1.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10636922","citation_count":75,"is_preprint":false},{"pmid":"10231540","id":"PMC_10231540","title":"A conformational change in the human major histocompatibility complex protein HLA-DR1 induced by peptide binding.","date":"1999","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10231540","citation_count":73,"is_preprint":false},{"pmid":"7738039","id":"PMC_7738039","title":"TATA-binding protein residues implicated in a functional interplay between negative cofactor NC2 (Dr1) and general factors TFIIA and TFIIB.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7738039","citation_count":69,"is_preprint":false},{"pmid":"9121744","id":"PMC_9121744","title":"Association between Vogt-Koyanagi-Harada syndrome and HLA-DR1 and -DR4 in Hispanic patients living in southern California.","date":"1995","source":"Ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/9121744","citation_count":67,"is_preprint":false},{"pmid":"8523575","id":"PMC_8523575","title":"Specific hepatitis B virus minus-strand DNA synthesis requires only the 5' encapsidation signal and the 3'-proximal direct repeat DR1.","date":"1996","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/8523575","citation_count":67,"is_preprint":false},{"pmid":"7679697","id":"PMC_7679697","title":"Differential effect of polymorphism at HLA-DR1 beta-chain positions 85 and 86 on binding and recognition of DR1-restricted antigenic peptides.","date":"1993","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7679697","citation_count":66,"is_preprint":false},{"pmid":"8022773","id":"PMC_8022773","title":"Interaction of the Dr1 inhibitory factor with the TATA binding protein is disrupted by adenovirus E1A.","date":"1994","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8022773","citation_count":65,"is_preprint":false},{"pmid":"10980387","id":"PMC_10980387","title":"Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response.","date":"2000","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10980387","citation_count":61,"is_preprint":false},{"pmid":"7939686","id":"PMC_7939686","title":"Differential regulation of RNA polymerases I, II, and III by the TBP-binding repressor Dr1.","date":"1994","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/7939686","citation_count":60,"is_preprint":false},{"pmid":"20629796","id":"PMC_20629796","title":"Contribution of quorum-sensing system to hexadecane degradation and biofilm formation in Acinetobacter sp. strain DR1.","date":"2010","source":"Journal of applied microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/20629796","citation_count":59,"is_preprint":false},{"pmid":"17507491","id":"PMC_17507491","title":"Direct ex vivo analyses of HLA-DR1 transgenic mice reveal an exceptionally broad pattern of immunodominance in the primary HLA-DR1-restricted CD4 T-cell response to influenza virus hemagglutinin.","date":"2007","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/17507491","citation_count":56,"is_preprint":false},{"pmid":"26884212","id":"PMC_26884212","title":"Endogenous hydrogen peroxide increases biofilm formation by inducing exopolysaccharide production in Acinetobacter oleivorans DR1.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26884212","citation_count":56,"is_preprint":false},{"pmid":"19386707","id":"PMC_19386707","title":"Infection of HLA-DR1 transgenic mice with a human isolate of influenza a virus (H1N1) primes a diverse CD4 T-cell repertoire that includes CD4 T cells with heterosubtypic cross-reactivity to avian (H5N1) influenza virus.","date":"2009","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/19386707","citation_count":55,"is_preprint":false},{"pmid":"1833450","id":"PMC_1833450","title":"T cell receptor gene segment utilization by HLA-DR1-alloreactive T cell clones.","date":"1991","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1833450","citation_count":52,"is_preprint":false},{"pmid":"21900604","id":"PMC_21900604","title":"Affinity maturation of human CD4 by yeast surface display and crystal structure of a CD4-HLA-DR1 complex.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21900604","citation_count":45,"is_preprint":false},{"pmid":"14757758","id":"PMC_14757758","title":"Monoclonal antibodies specific for the empty conformation of HLA-DR1 reveal aspects of the conformational change associated with peptide binding.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14757758","citation_count":45,"is_preprint":false},{"pmid":"8618863","id":"PMC_8618863","title":"Isolation of HLA-DR1.(staphylococcal enterotoxin A)2 trimers in solution.","date":"1995","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8618863","citation_count":43,"is_preprint":false},{"pmid":"2930600","id":"PMC_2930600","title":"Class II major histocompatibility complex gene sequences in rheumatoid arthritis. The third diversity regions of both DR beta 1 genes in two DR1, DRw10-positive individuals specify the same inferred amino acid sequence as the DR beta 1 and DR beta 2 genes of a DR4 (Dw14) haplotype.","date":"1989","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/2930600","citation_count":42,"is_preprint":false},{"pmid":"8456440","id":"PMC_8456440","title":"HLA-DR1 and rheumatoid arthritis in Israeli Jews: sequencing reveals that DRB1*0102 is the predominant HLA-DR1 subtype.","date":"1993","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/8456440","citation_count":41,"is_preprint":false},{"pmid":"16229453","id":"PMC_16229453","title":"Probing the ligand-induced conformational change in HLA-DR1 by selective chemical modification and mass spectrometric mapping.","date":"2005","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16229453","citation_count":41,"is_preprint":false},{"pmid":"34819392","id":"PMC_34819392","title":"CD8+ T Cells Expressing an HLA-DR1 Chimeric Antigen Receptor Target Autoimmune CD4+ T Cells in an Antigen-Specific Manner and Inhibit the Development of Autoimmune Arthritis.","date":"2021","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/34819392","citation_count":40,"is_preprint":false},{"pmid":"12477712","id":"PMC_12477712","title":"Hypoxia actively represses transcription by inducing negative cofactor 2 (Dr1/DrAP1) and blocking preinitiation complex assembly.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12477712","citation_count":39,"is_preprint":false},{"pmid":"29717211","id":"PMC_29717211","title":"Up-regulation of microRNA-203 in influenza A virus infection inhibits viral replication by targeting DR1.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29717211","citation_count":37,"is_preprint":false},{"pmid":"7687299","id":"PMC_7687299","title":"Recombinant human hepatitis B virus reverse transcriptase is active in the absence of the nucleocapsid or the viral replication origin, DR1.","date":"1993","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/7687299","citation_count":37,"is_preprint":false},{"pmid":"28857443","id":"PMC_28857443","title":"Metabolic and stress responses of Acinetobacter oleivorans DR1 during long-chain alkane degradation.","date":"2017","source":"Microbial biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/28857443","citation_count":36,"is_preprint":false},{"pmid":"12482672","id":"PMC_12482672","title":"A pregenomic RNA sequence adjacent to DR1 and complementary to epsilon influences hepatitis B virus replication efficiency.","date":"2002","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/12482672","citation_count":35,"is_preprint":false},{"pmid":"15778354","id":"PMC_15778354","title":"Ex vivo characterization of the autoimmune T cell response in the HLA-DR1 mouse model of collagen-induced arthritis reveals long-term activation of type II collagen-specific cells and their presence in arthritic joints.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15778354","citation_count":35,"is_preprint":false},{"pmid":"8836190","id":"PMC_8836190","title":"Protein-protein interaction between the transcriptional repressor E4BP4 and the TBP-binding protein Dr1.","date":"1996","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/8836190","citation_count":35,"is_preprint":false},{"pmid":"6199211","id":"PMC_6199211","title":"Influenza A hemagglutinin-specific T cell clones strictly restricted by HLA-DR1 or HLA-DR7 molecules.","date":"1984","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/6199211","citation_count":35,"is_preprint":false},{"pmid":"2453563","id":"PMC_2453563","title":"Polymorphism of the HLA-DR1 haplotype in American blacks. Identification of a DR1 beta-chain determinant recognized in the mixed lymphocyte reaction.","date":"1988","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/2453563","citation_count":34,"is_preprint":false},{"pmid":"1688595","id":"PMC_1688595","title":"Evolution of the HLA-DR1 gene family. Structural and functional analysis of the new allele \"DR-BON\".","date":"1990","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1688595","citation_count":33,"is_preprint":false},{"pmid":"1353916","id":"PMC_1353916","title":"T cell receptor V beta gene usage in HLA-DR1-reactive human T cell populations. The predominance of V beta 8.","date":"1992","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/1353916","citation_count":33,"is_preprint":false},{"pmid":"8972183","id":"PMC_8972183","title":"Functional dissection of a human Dr1-DRAP1 repressor complex.","date":"1997","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8972183","citation_count":33,"is_preprint":false},{"pmid":"35606087","id":"PMC_35606087","title":"Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma.","date":"2022","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35606087","citation_count":33,"is_preprint":false},{"pmid":"1683235","id":"PMC_1683235","title":"Association of rheumatoid arthritis with a dominant DR1/Dw4/Dw14 sequence motif, but not with T cell receptor beta chain gene alleles or haplotypes.","date":"1991","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/1683235","citation_count":33,"is_preprint":false},{"pmid":"1573265","id":"PMC_1573265","title":"Mutations in the third, but not the first or second, hypervariable regions of DR(beta 1*0101) eliminate DR1-restricted recognition of a pertussis toxin peptide.","date":"1992","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1573265","citation_count":33,"is_preprint":false},{"pmid":"12817001","id":"PMC_12817001","title":"A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12817001","citation_count":33,"is_preprint":false},{"pmid":"10852970","id":"PMC_10852970","title":"The C-terminal domain-phosphorylated IIO form of RNA polymerase II is associated with the transcription repressor NC2 (Dr1/DRAP1) and is required for transcription activation in human nuclear extracts.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10852970","citation_count":32,"is_preprint":false},{"pmid":"8381833","id":"PMC_8381833","title":"Nonrandom T cell receptor usage in the allorecognition of HLA-DR1 microvariation.","date":"1993","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8381833","citation_count":31,"is_preprint":false},{"pmid":"8648740","id":"PMC_8648740","title":"Human cytomegalovirus immediate-early 2 (IE2) protein can transactivate the human hsp70 promoter by alleviation of Dr1-mediated repression.","date":"1996","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/8648740","citation_count":31,"is_preprint":false},{"pmid":"25330344","id":"PMC_25330344","title":"Global transcriptome and physiological responses of Acinetobacter oleivorans DR1 exposed to distinct classes of antibiotics.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25330344","citation_count":30,"is_preprint":false},{"pmid":"9604008","id":"PMC_9604008","title":"Functional interactions between nuclear receptors recognizing a common sequence element, the direct repeat motif spaced by one nucleotide (DR-1).","date":"1998","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9604008","citation_count":30,"is_preprint":false},{"pmid":"25511986","id":"PMC_25511986","title":"Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats.","date":"2014","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/25511986","citation_count":30,"is_preprint":false},{"pmid":"12483744","id":"PMC_12483744","title":"Peptide-induced suppression of collagen-induced arthritis in HLA-DR1 transgenic mice.","date":"2002","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/12483744","citation_count":29,"is_preprint":false},{"pmid":"21538240","id":"PMC_21538240","title":"Physiological and metabolic responses for hexadecane degradation in Acinetobacter oleivorans DR1.","date":"2011","source":"Journal of microbiology (Seoul, Korea)","url":"https://pubmed.ncbi.nlm.nih.gov/21538240","citation_count":28,"is_preprint":false},{"pmid":"17617623","id":"PMC_17617623","title":"Human cytotoxic CD4+ T cells recognize HLA-DR1-restricted epitopes on vaccinia virus proteins A24R and D1R conserved among poxviruses.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17617623","citation_count":28,"is_preprint":false},{"pmid":"8270868","id":"PMC_8270868","title":"Membrane interactions influence the peptide binding behavior of DR1.","date":"1994","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8270868","citation_count":27,"is_preprint":false},{"pmid":"21856821","id":"PMC_21856821","title":"Comparative genomic analysis of Acinetobacter oleivorans DR1 to determine strain-specific genomic regions and gentisate biodegradation.","date":"2011","source":"Applied and environmental microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/21856821","citation_count":27,"is_preprint":false},{"pmid":"2022496","id":"PMC_2022496","title":"DNA typing for class II HLA antigens with allele-specific or group-specific amplification. V. Typing for subsets of HLA-DR1 and DR'Br'.","date":"1991","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/2022496","citation_count":27,"is_preprint":false},{"pmid":"6420499","id":"PMC_6420499","title":"Analysis of the structural heterogeneity and polymorphism of human Ia antigens. Four distinct subsets of molecules are coexpressed in the Ia pool of both DR1,1 homozygous and DR3,W6 heterozygous B cell lines.","date":"1984","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/6420499","citation_count":27,"is_preprint":false},{"pmid":"8778037","id":"PMC_8778037","title":"Interaction of natural killer cells with MHC class II: reversal of HLA-DR1-mediated protection of K562 transfectant from natural killer cell-mediated cytolysis by brefeldin-A.","date":"1996","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8778037","citation_count":27,"is_preprint":false},{"pmid":"12009208","id":"PMC_12009208","title":"Stabilization of soluble, low-affinity HLA-DM/HLA-DR1 complexes by leucine zippers.","date":"2002","source":"Journal of immunological methods","url":"https://pubmed.ncbi.nlm.nih.gov/12009208","citation_count":25,"is_preprint":false},{"pmid":"12952957","id":"PMC_12952957","title":"Exploration of the P6/P7 region of the peptide-binding site of the human class II major histocompatability complex protein HLA-DR1.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12952957","citation_count":25,"is_preprint":false},{"pmid":"25310094","id":"PMC_25310094","title":"Immunogenicity evaluation of a rationally designed polytope construct encoding HLA-A*0201 restricted epitopes derived from Leishmania major related proteins in HLA-A2/DR1 transgenic mice: steps toward polytope vaccine.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25310094","citation_count":25,"is_preprint":false},{"pmid":"12941540","id":"PMC_12941540","title":"Inhibition of T-cell activation with HLA-DR1/DR4 restricted Non-T-cell stimulating peptides.","date":"2003","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12941540","citation_count":24,"is_preprint":false},{"pmid":"25589657","id":"PMC_25589657","title":"A host susceptibility gene, DR1, facilitates influenza A virus replication by suppressing host innate immunity and enhancing viral RNA replication.","date":"2015","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/25589657","citation_count":24,"is_preprint":false},{"pmid":"6411812","id":"PMC_6411812","title":"Dissociation in expression of MB1/MT1 and DR1 alloantigens in mutants of a lymphoblastoid cell line.","date":"1983","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/6411812","citation_count":24,"is_preprint":false},{"pmid":"18507432","id":"PMC_18507432","title":"Vaccinia peptides eluted from HLA-DR1 isolated from virus-infected cells are recognized by CD4+ T cells from a vaccinated donor.","date":"2008","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/18507432","citation_count":24,"is_preprint":false},{"pmid":"22871092","id":"PMC_22871092","title":"Association of HLA-DR1 with the allergic response to the major mugwort pollen allergen: molecular background.","date":"2012","source":"BMC immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22871092","citation_count":23,"is_preprint":false},{"pmid":"15144476","id":"PMC_15144476","title":"Association of HLA-DQ5 and HLA-DR1 with sensitization to organic acid anhydrides.","date":"2004","source":"Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15144476","citation_count":23,"is_preprint":false},{"pmid":"16447222","id":"PMC_16447222","title":"The impact of glycosylation on HLA-DR1-restricted T cell recognition of type II collagen in a mouse model.","date":"2006","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/16447222","citation_count":23,"is_preprint":false},{"pmid":"1716292","id":"PMC_1716292","title":"Structural analysis of anti-DR1 allorecognition by using DR1/H-2Ek hybrid molecules. Influence of the beta 2-domain correlates with CD4 dependence.","date":"1991","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1716292","citation_count":22,"is_preprint":false},{"pmid":"1313575","id":"PMC_1313575","title":"Interaction of the pertussis toxin peptide containing residues 30-42 with DR1 and the T-cell receptors of 12 human T-cell clones.","date":"1992","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1313575","citation_count":22,"is_preprint":false},{"pmid":"1353488","id":"PMC_1353488","title":"Molecular characterization of a recombinant HLA-DR1/DR2 haplotype.","date":"1992","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/1353488","citation_count":22,"is_preprint":false},{"pmid":"6581120","id":"PMC_6581120","title":"Structural polymorphism of the DC1 light chains from DR1-, DR2-, and DRw6-positive cell lines.","date":"1983","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/6581120","citation_count":22,"is_preprint":false},{"pmid":"3486708","id":"PMC_3486708","title":"The relation of susceptibility to and biologic behavior of thyroid epithelial cell cancer to HLA-DR1.","date":"1986","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/3486708","citation_count":21,"is_preprint":false},{"pmid":"8702484","id":"PMC_8702484","title":"A negative cofactor containing Dr1/p19 modulates transcription with TFIIA in a promoter-specific fashion.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8702484","citation_count":20,"is_preprint":false},{"pmid":"10498237","id":"PMC_10498237","title":"Possible association of human leucocyte antigen DR1 with delayed sleep phase syndrome.","date":"1999","source":"Psychiatry and clinical neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/10498237","citation_count":20,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":45936,"output_tokens":3921,"usd":0.098311,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":11639,"output_tokens":3678,"usd":0.075073,"stage2_stop_reason":"end_turn"},"total_usd":0.173384,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1992,\n      \"finding\": \"DR1 (Down-regulator of transcription 1) interacts directly with the TATA-binding protein (TBP), and this association represses both basal and activated transcription by blocking the association of TFIIA and/or TFIIB with TBP, preventing formation of a transcription-competent preinitiation complex. DR1 activity is associated with a 19 kDa phosphoprotein, and phosphorylation of DR1 affects its interaction with TBP.\",\n      \"method\": \"Biochemical purification, in vitro transcription repression assay, Co-immunoprecipitation, cDNA cloning, phosphorylation analysis\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 / Strong — original discovery paper with multiple orthogonal methods (in vitro transcription assay, protein-protein interaction, cDNA cloning), foundational mechanistic result replicated by multiple subsequent studies\",\n      \"pmids\": [\"1339312\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"DR1 directly interacts with the multiprotein TFIID complex (not just free TBP) in vivo via a yeast two-hybrid assay. Two distinct domains of DR1 are required for repression: a TBP-binding domain and an alanine-rich domain. DR1-mediated repression can be reversed by overexpression of TBP in vivo, and Dr1 can repress transcription from both TATA-containing and TATA-less promoters.\",\n      \"method\": \"Yeast two-hybrid, in vitro binding assays, transient transfection, domain-deletion mutagenesis\",\n      \"journal\": \"Genes & Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods (yeast two-hybrid, in vivo overexpression rescue, mutagenesis) in a single focused study, confirmed by subsequent papers\",\n      \"pmids\": [\"7958881\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"NC2 (negative cofactor 2) is identical to DR1. TBP residues Lys-133, Lys-145, and Lys-151 in the basic repeat region are important for NC2/DR1 interaction, whereas Leu-189 is required for TFIIB interaction, demonstrating that distinct TBP surface regions mediate interactions with DR1/NC2 versus TFIIB.\",\n      \"method\": \"TBP mutagenesis, in vitro binding assays, transcription reconstitution\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis combined with in vitro reconstitution, establishes molecular identity of NC2=DR1 and maps binding surfaces on TBP\",\n      \"pmids\": [\"7738039\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"A DR1-associated polypeptide (DRAP1, also called NC2-alpha or NC2β partner) was isolated and functions as a corepressor requiring interaction with DR1. Heterodimer formation between DRAP1 and DR1 depends on a histone fold motif at the amino terminus of both polypeptides. The DRAP1–DR1 complex increases the stability of the DR1–TBP–TATA motif complex and more effectively precludes TFIIA and/or TFIIB entry into preinitiation complexes.\",\n      \"method\": \"Protein purification, Co-immunoprecipitation, in vitro transcription assay, domain analysis\",\n      \"journal\": \"Genes & Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — biochemical purification, functional reconstitution, and domain mapping; replicated by subsequent studies confirming the DR1/DRAP1 heterodimer\",\n      \"pmids\": [\"8608938\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"DR1 selectively represses RNA polymerase II and RNA polymerase III transcription by binding TBP and blocking polymerase-specific factor interactions, but does not inhibit RNA polymerase I transcription under the same conditions, enabling coordinate regulation of Pol II and Pol III while sparing Pol I.\",\n      \"method\": \"In vitro transcription assays with purified components, selective depletion/add-back experiments\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstituted transcription system with three polymerases compared, single lab but rigorous biochemical approach\",\n      \"pmids\": [\"7939686\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Adenovirus E1A 12S protein disrupts the DR1–TBP interaction in a manner dependent on N-terminal E1A sequences, thereby allowing productive TBP–TFIIA interaction and relieving DR1-mediated repression of the hsp70 promoter in vivo.\",\n      \"method\": \"Co-immunoprecipitation, in vitro protein interaction assay, transient transfection with wild-type and mutant E1A\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — Co-IP and in vivo functional rescue, two methods, single lab\",\n      \"pmids\": [\"8022773\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Human cytomegalovirus IE2 protein overcomes DR1-mediated transcriptional repression of the hsp70 promoter in vivo. IE2 physically interacts with DR1 both in vivo and in vitro, and can prevent DR1-mediated inhibition of TBP DNA binding in vitro, suggesting a mechanism for TATA-dependent IE2 transactivation.\",\n      \"method\": \"Co-immunoprecipitation (in vivo and in vitro), in vitro TBP DNA binding assay, transient transfection\",\n      \"journal\": \"Journal of Virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — multiple methods (Co-IP in vivo and in vitro, functional in vitro binding assay), single lab\",\n      \"pmids\": [\"8648740\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"DR1 contains two functional domains: a tethering domain that interacts with TBP (required to direct the repressor to the promoter) and a repression domain (glutamine-alanine rich). The repression domain alone (65 aa), fused to the Gal4 DNA-binding domain, represses transcription from TATA-containing and TATA-less promoters. DRAP1 enhances DR1-mediated repression only when the tethering domain is present.\",\n      \"method\": \"Domain deletion and fusion constructs, in vitro transcription assays, transient transfection\",\n      \"journal\": \"Molecular and Cellular Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — domain-swapping mutagenesis combined with functional assays in vitro and in vivo; replicated and extended prior work\",\n      \"pmids\": [\"8972183\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The yeast DR1/DRAP1 homologs (YDR1/BUR6) are encoded by two essential genes. Human DR1 and DRAP1 can rescue lethality caused by deletion of the yeast genes, but human DRAP1 only functions when human DR1 is co-expressed. Overexpression of YDR1 decreases mRNA accumulation and impairs growth, rescuable by TBP overexpression. DR1 overexpression affects Pol II and Pol III but not Pol I transcript levels in vivo, demonstrating it is a global repressor in vivo.\",\n      \"method\": \"Yeast genetics (deletion, rescue by human homologs), in vitro reconstituted transcription, in vivo mRNA quantification\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in yeast combined with in vitro transcription reconstitution; replicates earlier in vitro findings in a cellular system\",\n      \"pmids\": [\"9023340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The transcriptional repressor E4BP4 interacts specifically with DR1 through its C-terminal repression domain. E4BP4 mutants deficient in transcriptional repression are also deficient in DR1 binding, suggesting DR1 mediates at least part of E4BP4's repression activity.\",\n      \"method\": \"Co-immunoprecipitation/pull-down, transient transfection with repression domain mutants\",\n      \"journal\": \"Nucleic Acids Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — single Co-IP/pulldown, supported by correlation between DR1-binding and repression function via mutagenesis\",\n      \"pmids\": [\"8836190\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"DR1 (NC2β) forms a complex with CTD-hyperphosphorylated RNA polymerase IIO (but not unphosphorylated RNAP IIA or CTD-less RNAP IIB). In unfractionated HeLa nuclear extracts, immunodepletion of NC2/DR1 does not significantly affect basal transcription but dramatically reduces activated transcription, revealing an unexpected positive role for DR1 in activated transcription in the context of native nuclear extracts.\",\n      \"method\": \"Co-immunoprecipitation with purified factors, immunodepletion from HeLa nuclear extracts, in vitro transcription assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — reconstituted and native extract biochemistry, co-IP with purified factors; single lab, novel finding regarding DR1 positive role\",\n      \"pmids\": [\"10852970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Hypoxic stress induces upregulation of NC2 (Dr1/DrAP1) protein, which binds core promoters and blocks preinitiation complex assembly and RNA Pol II CTD phosphorylation. Immunodepletion of NC2β/Dr1 from hypoxic cell extracts rescues repressed transcription without affecting normoxic transcription, demonstrating that hypoxia actively represses transcription via Dr1.\",\n      \"method\": \"In vitro transcription reconstitution, immunodepletion, immunoblot, hypoxic cell extract analysis\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — functional immunodepletion rescue experiment combined with in vitro transcription; single lab\",\n      \"pmids\": [\"12477712\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"A negative cofactor containing Dr1/p19 (heterotetramer with a 30-kDa partner, proposed as DRAP1 homolog) forms a complex with TBP on DNA protecting ~150 bp around the promoter from DNase I cleavage. TFIIA reverses this repression and alters complex conformation in a promoter-specific fashion: on the adenovirus MLP but not on the immunoglobulin mu promoter.\",\n      \"method\": \"Protein purification, DNase I footprinting, in vitro transcription assay, TFIIA competition\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — biochemical reconstitution with footprinting and transcription assays; single lab, promoter-specific distinction established\",\n      \"pmids\": [\"8702484\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"DR1 (the transcriptional repressor) is a positive host factor for influenza A virus (IAV) replication. Knockdown of DR1 reduces viral RNA and protein production. DR1 suppresses IFN-β induction (and downstream ISG expression) in normal cells, and also directly enhances viral RNA-dependent RNA polymerase (RdRp) activity by physically associating with all three subunits of the viral RdRp complex.\",\n      \"method\": \"Genome-wide RNAi screen, siRNA knockdown, genome-wide transcriptomics, viral RNA replication biochemical assay, Co-immunoprecipitation of DR1 with viral RdRp subunits\",\n      \"journal\": \"Journal of Virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — RNAi screen validated by targeted KD, transcriptomics, biochemical RdRp assay, and Co-IP; single lab\",\n      \"pmids\": [\"25589657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"DR1 is a direct target of miR-203, which is upregulated during influenza A virus (H5N1) infection. Silencing DR1 by siRNA in miR-203 knockout cells inhibits H5N1 replication similarly to miR-203 overexpression, confirming DR1's role as a positive regulator of IAV replication downstream of miR-203.\",\n      \"method\": \"miRNA overexpression/knockout, siRNA knockdown, viral replication assay, target validation\",\n      \"journal\": \"Scientific Reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — functional genetic validation of DR1 as miR-203 target with siRNA rescue experiment; single lab\",\n      \"pmids\": [\"29717211\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"DR1 (Down-regulator of transcription 1, also NC2-beta/NC2B) is a transcriptional repressor that binds TBP via a histone-fold-containing tethering domain, blocking recruitment of TFIIA and TFIIB to preinitiation complexes, thereby repressing RNA Pol II and Pol III but not Pol I transcription; its repressor activity is enhanced by heterodimerization with DRAP1 (NC2-alpha) through their shared histone fold motifs, can be relieved by viral proteins (adenovirus E1A, HCMV IE2) that disrupt the DR1–TBP interaction, and is physiologically induced by hypoxia; DR1 also physically associates with all three subunits of the influenza A virus RdRp complex, directly facilitating viral RNA replication while simultaneously suppressing host IFN-β induction.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"DR1 (Down-regulator of transcription 1, identical to NC2-beta/NC2) is a global transcriptional repressor that acts at the core of the RNA polymerase II preinitiation complex by binding directly to the TATA-binding protein (TBP) and to the TFIID complex [#0, #1, #2]. It engages a distinct surface of TBP (basic-repeat residues Lys-133/145/151) separate from the TFIIB-interaction surface, and by occupying TBP it blocks the entry of TFIIA and TFIIB, preventing assembly of a transcription-competent complex on both TATA-containing and TATA-less promoters [#0, #1, #2]. The protein is functionally bipartite: a TBP-binding tethering domain directs it to the promoter while a glutamine/alanine-rich repression domain delivers the silencing activity, the latter sufficient to repress transcription when independently tethered [#7]. Repression is potentiated by heterodimerization with DRAP1 (NC2-alpha) through a shared N-terminal histone-fold motif, which stabilizes the DR1-TBP-TATA complex and more effectively excludes the general factors; this exclusion is reversed by TFIIA in a promoter-specific manner [#3, #7, #12]. DR1 selectively represses RNA polymerase II and III transcription while sparing Pol I, and this global repressive role is conserved, as the human protein and its yeast YDR1/BUR6 homologs are functionally interchangeable and essential [#4, #8]. DR1-mediated repression is a regulatory node exploited and modulated in physiological and pathogenic contexts: it is induced by hypoxic stress to actively shut down transcription [#11], is relieved by viral activators adenovirus E1A and HCMV IE2 that disrupt the DR1-TBP interaction [#5, #6], and is co-opted as a positive host factor for influenza A virus, where DR1 associates with all three subunits of the viral RdRp to enhance viral RNA synthesis while suppressing IFN-beta induction [#13, #14].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Established the founding mechanism: how a cellular factor could repress basal and activated transcription at the level of the general machinery rather than at specific activators.\",\n      \"evidence\": \"Biochemical purification, in vitro transcription repression, Co-IP and cDNA cloning identifying direct DR1-TBP binding that blocks TFIIA/TFIIB\",\n      \"pmids\": [\"1339312\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Domain organization of DR1 not yet mapped\", \"Role of the 19 kDa phosphoprotein and phosphorylation regulation left unresolved\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Resolved which polymerases DR1 acts on, showing selective repression of Pol II and Pol III but not Pol I, defining the scope of its global regulatory function.\",\n      \"evidence\": \"In vitro transcription with purified components comparing all three polymerases; in vivo TFIID interaction and TBP-overexpression rescue\",\n      \"pmids\": [\"7939686\", \"7958881\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Basis for sparing Pol I not mechanistically explained\", \"In vivo promoter occupancy not addressed\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Unified NC2 and DR1 as one factor and mapped the TBP surfaces that distinguish DR1 binding from TFIIB binding, explaining the competitive mechanism.\",\n      \"evidence\": \"TBP mutagenesis with in vitro binding and transcription reconstitution\",\n      \"pmids\": [\"7738039\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural detail of the DR1-TBP-DNA complex not resolved at this stage\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Identified DRAP1 as the obligate corepressor partner and established the histone-fold heterodimer as the active repressive unit that stabilizes the TBP-DNA complex.\",\n      \"evidence\": \"Protein purification, Co-IP, in vitro transcription and domain analysis; DNase I footprinting of the heterotetramer protecting ~150 bp\",\n      \"pmids\": [\"8608938\", \"8702484\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Promoter-specific TFIIA reversal mechanism only partially defined\", \"Stoichiometry and architecture on chromatin not established\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Linked DR1 to a sequence-specific repressor (E4BP4), indicating DR1 can serve as the effector arm for promoter-targeted repressors.\",\n      \"evidence\": \"Co-IP/pull-down with E4BP4 repression-domain mutants showing correlated binding and repression\",\n      \"pmids\": [\"8836190\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single Co-IP/pulldown without reciprocal in vitro reconstitution\", \"Whether E4BP4 recruits DR1 to specific genes in vivo unknown\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Dissected DR1 into a tethering domain and a separable repression domain, defining how promoter targeting and silencing activity are functionally partitioned.\",\n      \"evidence\": \"Domain-deletion and Gal4-fusion constructs with in vitro and in vivo transcription assays\",\n      \"pmids\": [\"8972183\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular targets of the repression domain beyond blocking TFIIA/TFIIB not identified\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Demonstrated in vivo and across evolution that DR1 is an essential global repressor, with conserved function between human and yeast homologs.\",\n      \"evidence\": \"Yeast genetics with human-homolog rescue, in vitro reconstituted transcription, in vivo mRNA quantification\",\n      \"pmids\": [\"9023340\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Gene-specific in vivo targets in higher eukaryotes not mapped\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Revealed a context-dependent positive role: in native nuclear extracts DR1 associates with hyperphosphorylated Pol IIO and is required for activated transcription, complicating the purely repressive model.\",\n      \"evidence\": \"Co-IP with purified Pol II forms and immunodepletion from HeLa nuclear extracts with transcription readout\",\n      \"pmids\": [\"10852970\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism reconciling repressive and activating roles unresolved\", \"Single-lab observation in native extracts\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Placed DR1 in a physiological stress pathway, showing hypoxia induces NC2/Dr1 to actively shut down transcription via PIC blockade and reduced CTD phosphorylation.\",\n      \"evidence\": \"In vitro transcription reconstitution, immunodepletion rescue from hypoxic extracts, immunoblot\",\n      \"pmids\": [\"12477712\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Upstream signal inducing NC2/Dr1 not defined\", \"Gene-selectivity of hypoxic repression not characterized\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Uncovered a pro-viral function: DR1 is a host factor that both suppresses IFN-beta induction and directly enhances influenza A RdRp activity through physical association with the polymerase.\",\n      \"evidence\": \"Genome-wide RNAi screen, siRNA knockdown, transcriptomics, RdRp biochemical assay, Co-IP with all three RdRp subunits\",\n      \"pmids\": [\"25589657\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether RdRp enhancement is mechanistically separate from transcriptional repression unclear\", \"Structural basis of DR1-RdRp interaction unknown\", \"Single lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Positioned DR1 within a host miRNA regulatory circuit, identifying it as a miR-203 target whose silencing limits H5N1 replication.\",\n      \"evidence\": \"miR-203 overexpression/knockout, siRNA knockdown with rescue, viral replication and target validation assays\",\n      \"pmids\": [\"29717211\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct miR-203:DR1 binding site validation limited\", \"How DR1 levels are tuned during infection in vivo not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How DR1's repressive activity, its positive role in activated transcription, and its pro-viral RdRp-enhancing function are mechanistically integrated remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of DR1-DRAP1-TBP-DNA on native promoters\", \"Genome-wide in vivo occupancy and gene-selectivity unmapped\", \"Reconciliation of repressor versus activator/coactivator roles unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 4, 7, 8]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 3, 7]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [3, 7]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [11, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 1, 4, 8]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [11]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [13, 14]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [13]}\n    ],\n    \"complexes\": [\"NC2 (DR1-DRAP1) repressor heterodimer\"],\n    \"partners\": [\"TBP\", \"DRAP1\", \"TFIID\", \"E4BP4\", \"RNA polymerase II\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}